Skip to main content

Table 1 Summary table for overall survival with HR and rmstD at t* = 5 years and 10 years and their respective confidence intervals for each trial comparison of the network meta-analysis

From: Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas

Trial comparison

Treatment comparison

HR

CI 95%

p value test for non-proportionality

rmstD (m) t* = 5 years

CI 95%

rmstD (m) t* = 10 years

CI 95%

AOCOA

IC-RT vs. RT

0.99

[0.68; 1.44]

0.60

0.66

[− 4.05; 5.36]

− 0.39

[− 12.15; 11.36]

VUMCA-89

IC-RT vs. RT

1.00

[0.75; 1.33]

0.49

0.56

[− 4.34; 5.45]

0.73

[− 10.06; 11.52]

Japan-91

IC-RT vs. RT

0.77

[0.40; 1.46]

0.27

0.91

[− 6.21; 8.02]

9.44*

[− 10.19; 29.07]

PWHQEH-94

CRT vs. RT

0.81

[0.61; 1.07]

0.11

4.24

[0.69; 7.79]

9.11

[0.14; 18.08]

QMH-95Conc‡

CRT vs. RT

1.00

[0.57; 1.75]

0.75

1.18

[− 4.18; 6.54]

− 0.30

[− 14.83; 14.24]

Guangzhou 2001

CRT vs. RT

0.54

[0.31; 0.93]

0.080

7.90

[1.98; 13.82]

17.94

[2.53; 33.35]

Guangzhou 2003

CRT vs. RT

0.34

[0.18; 0.66]

0.91

1.95

[0.06; 3.84]

10.29*

[3.71; 16.87]

INT-0099

CRT-AC vs. RT

0.50

[0.36; 0.71]

0.11

11.92

[6.13; 17.71]

27.08

[14.27; 39.89]

QMH-95Comp5‡^

CRT-AC vs. RT

0.65

[0.36; 1.19]

0.79

1.79

[− 3.67; 7.25]

8.02

[− 6.05; 22.08]

SQNP01

CRT-AC vs. RT

0.68

[0.48; 0.96]

0.52

5.30

[0.45; 10.14]

14.30

[2.90; 25.70]

NPC-9901

CRT-AC vs. RT

0.73

[0.54; 0.99]

0.24

1.50

[− 2.37; 5.37]

6.58

[− 2.75; 15.91]

NPC-9902CF

CRT-AC vs. RT

0.97

[0.52; 1.82]

0.53

1.67

[− 4.55; 7.88]

2.94

[− 13.50; 19.37]

NPC-9902AF

CRT-AC vs. RT

0.50

[0.28; 0.90]

0.76

6.37

[0.67; 12.07]

16.73

[1.48; 31.97]

Guangzhou 2002-01

CRT-AC vs. RT

0.69

[0.48; 0.99]

0.16

4.68

[0.97; 8.38]

7.21*

[− 3.21; 17.64]

TCOG-94

RT-AC vs. RT

0.95

[0.65; 1.40]

0.24

− 1.52

[− 7.94; 4.90]

1.57

[−13.01; 16.15]

QMH-95Adj‡

RT-AC vs. RT

1.07

[0.61; 1.89]

0.30

− 3.24

[−  9.54; 3.05]

− 6.55

[− 22.30; 9.21]

VUMCA-95

IC-CRT vs. IC-RT

0.89

[0.69; 1.16]

0.58

0.67

[− 3.05; 4.40]

4.33*

[− 5.07; 13.73]

Guangzhou 2002-02

IC-CRT vs. IC-RT

0.95

[0.69; 1.30]

0.027

− 1.63

[− 4.83; 1.58]

0.60*

[− 7.68; 8.87]

NPC008

CRT vs. IC-CRT

1.57

[0.72; 3.41]

0.030

− 9.82

[− 17.31; − 2.34]

− 18.16*

[− 37.67; 1.36]

HeCOG

CRT vs. IC-CRT

1.01

[0.60; 1.68]

0.48

− 0.03

[− 6.98; 6.92]

− 0.91*

[− 16.86; 15.04]

QMH-95Adj+‡

CRT-AC vs. CRT

0.66

[0.36; 1.19]

0.99

0.61

[− 4.28; 5.51]

8.32

[− 5.36; 21.99]

Guangzhou 2006

CRT-AC vs. CRT

0.79

[0.47; 1.30]

0.85

1.53

[− 0.84; 3.89]

6.30*

[− 3.20; 15.80]

QMH-95Conc+‡

RT-AC vs. CRT-AC

1.59

[0.87; 2.91]

0.24

− 5.03

[− 10.94; 0.88]

− 14.56

[− 29.53; 0.40]

QMH-95Comp6‡^

RT-AC vs. CRT

1.07

[0.61; 1.87]

0.11

− 4.42

[− 10.23; 1.40]

− 6.25

[− 21.66; 9.16]

PWH-88

IC-RT-AC vs. RT

1.30

[0.62; 2.73]

0.78

− 3.28

[− 12.56; 6.01]

− 9.17*

[− 32.69; 14.36]

Shanghai 2004

IC-RT-AC vs. CRT-AC

1.15

[0.61; 1.81]

0.80

− 0.32

[− 2.41; 1.78]

− 3.57*

[− 12.52; 5.39]

  1. CI confidence intervals; HR hazard ratio; m months; rmstD restricted mean survival time difference; PWH Prince of Wales Hospital; AOCOA Asian-Oceanian Clinical Oncology Association; VUMCA International Nasopharynx Cancer Study Group (cavum); PWHQEH Prince of Wales Hospital, Queen Elizabeth Hospital; INT-0099 SWOG (Southwest Oncology Group)-coordinated Intergroup trial, also known as SWOG 8892; QMH Queen Mary Hospital; SQNP Singapore Naso-Pharynx; NPC nasopharyngeal carcinoma; CF conventional fractionation; AF accelerated fractionation; TCOG Taiwan Cooperative Oncology Group; HeCOG Hellenic Cooperative Oncology Group; RT radiotherapy; IC induction chemotherapy; CRT concomitant chemoradiotherapy; AC adjuvant chemotherapy
  2. ‡QMH-95 trial, 2 × 2 design, considered as a multi-arm trial, and split into six comparisons
  3. *Extrapolation performed until 10 years using the Brown et al. method [16]
  4. ^Comparison estimated using individual patient data, required for computation of multi-arms trials